Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index; 95 of the 346 sources its claims cite were checked for support.
Abstract
Allometric scaling provides a practical framework for predicting human pharmacokinetic (PK) parameters from animal data by relating physiological processes to body size through power-law equations. Despite its simplicity and widespread use in first-in-human (FIH) dose selection, its predictive performance is limited by species-specific differences in absorption, distribution, metabolism, and excretion (ADME). This review summarizes the mathematical foundations, workflows, and diagnostics of allometric scaling, while critically examining where the approach succeeds and where it fails. Core concepts, including clearance, volume of distribution, correction factors, and the rule of exponents, are discussed alongside complementary methods: in vitro–in vivo extrapolation (IVIVE), physiologically based pharmacokinetic (PBPK) modelling, and the Wajima normalized time-course method. Historical clinical failures, including fialuridine, TGN1412, BIA 10-2474, and rofecoxib, illustrate the limits of relying solely on allometry, while thalidomide and the fenfluramine combination exemplify toxicodynamic species-selection failures. Modern advances, including the Extended Clearance Classification System (ECCS), target-mediated drug disposition, FcRn recycling, and emerging artificial intelligence and machine-learning methods, are integrated within a framework. Overall, the review treats allometric scaling as a disciplined starting hypothesis that must be triangulated with mechanistic, experimental, and regulatory evidence to support safer and more reliable human translation.
Overview
CoChat Summary
TL;DR
Allometric scaling remains a useful but limited starting hypothesis for predicting human pharmacokinetics from animal body weight, because species-specific ADME, transporter, target, and toxicodynamic biology often override size-based relationships. The review integrates classical allometry with correction factors, IVIVE, PBPK, ECCS, TMDD, Wajima normalization, and AI/ML into a mechanism-anchored decision framework for first-in-human dose prediction.
Key findings
- Kleiber’s basal metabolic rate scaling is approximately \(B = aM^{0.75}\), but the review notes the exponent is contested: empirical estimates for physiological and PK parameters typically fall between roughly 0.67 and 0.80, so 0.75 should be treated as a convenient default rather than a biophysical constant.
- In the worked clearance example, OLS regression gave \(\log_{10}(CL) = 0.603 \times \log_{10}(BW) + 0.931\), projecting human CL at 70 kg as approximately 110 mL/min; despite \(R^2 = 0.939\), the 95% confidence interval for the mean prediction spanned roughly 13–905 mL/min and the 95% prediction interval roughly 6–1970 mL/min.
- The rule of exponents recommends simple allometry when the exponent is 0.55–0.70, CL × maximum life-span potential when 0.71–1.0, and a two-term CL × brain-weight equation when the exponent exceeds 1.0; brain-weight correction factors were consistently larger than maximum-life-span factors by approximately 1.3–1.9.
- Lymphatic transport scales differently from systemic clearance: lymph flow and triglyceride mass transport scaled with exponents of approximately 0.84–0.94 and 0.80–0.96, while halofantrine lymphatic mass transport increased with an exponent of approximately 1.3; larger species such as dogs better resemble human lymphatic drug transport than rodents.
Methods
- Narrative, non-systematic review; sources were selected for conceptual and methodological relevance to interspecies PK scaling and first-in-human dose prediction, with emphasis on primary methodological papers, clinical case histories, and regulatory guidance rather than a registered systematic review protocol.
- The review synthesizes classical body-weight allometry, correction factors and the rule of exponents, IVIVE, PBPK, ECCS, target-mediated drug disposition, intestinal lymphatic transport, lysosomal sequestration, and AI/ML approaches into a proposed stepwise decision framework.
- Worked examples in Section 2.2 and Appendix A are hypothetical and constructed for didactic clarity; the Wajima worked example in Section 6.2 uses an independent hypothetical parameter set and is not numerically linked to the clearance example.
Limitations
- The paper states that predictive performance depends critically on the quality and number of preclinical species, with panels of three to four species typical but providing limited leverage; species choice often reflects historical convention rather than mechanistic relevance.
- The paper states that the allometry literature is subject to publication bias toward successful predictions, transporter-mediated scaling carries greater uncertainty than CYP-mediated scaling, idiosyncratic toxicities are not captured by any PK scaling framework, and retrospective benchmarks may not generalize to chemically novel modalities.
- Evident from the text, though not framed as a limitation: the review is non-systematic and does not perform a formal quantitative synthesis or meta-analysis, and its worked examples are hypothetical rather than empirical datasets.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
69 Valid · 20 Not valid · 92 Not checked · 24 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For monoclonal antibodies (mAbs) and other large biologic therapeutics, simple allometric scaling requires substantial adaptation [26,47].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 4. Where Size-Based Scaling Breaks > 4.5. Biologics and Target-Mediated Drug Disposition
What the sources say
- Disputedcites [26] Huh Y. Smith D.E. Rose Feng M. Interspecies Scaling and Prediction of Human Clearance: Comparison of Small- and Macro-Molecule Drugs Xenobiotica 2011 41 972 987 10.3109/00498254.2011.598582 21892879 PMC4181675 sourceExperimental — accuracy not yet measured
The Results (Scaling using single species; page unavailable) report that a fixed-exponent allometric equation generally predicted human clearance of macromolecule drugs well, with average-fold error below 2. The Discussion likewise says most predictions were within twofold. This contradicts the claim that simple allometric scaling requires substantial adaptation for these drugs. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [47] Wang W. Wang E. Balthasar J. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics Clin. Pharmacol. Ther. 2008 84 548 558 10.1038/clpt.2008.170 18784655 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“empirical estimates for individual physiological and pharmacokinetic parameters typically falling between roughly 0.67 and 0.80 [7,8].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 1. Introduction: Rationale for Allometric Scaling
What the sources say
- Partly supportedcites [7] White C.R. Seymour R.S. Mammalian Basal Metabolic Rate Is Proportional to Body Mass2/3 Proc. Natl. Acad. Sci. USA 2003 100 4046 4049 10.1073/pnas.0436428100 12637681 PMC153045 sourceExperimental — accuracy not yet measured
The Results report mammalian basal metabolic rate scaling exponents near 0.67, supporting one physiological example. The paper does not establish that individual physiological parameters typically fall between 0.67 and 0.80, and it does not report pharmacokinetic parameter estimates. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] Dodds P.S. Rothman D.H. Weitz J.S. Re-Examination of the “3/4-Law” of Metabolism J. Theor. Biol. 2001 209 9 27 10.1006/jtbi.2000.2238 11237567 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Third, with only three to four species typically available, the 70 kg prediction intervals are necessarily wider than the point estimates alone would suggest [6,24].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 3. Mathematics and Diagnostics of the Log–Log Line
What the sources say
- Not checked — no full text of the sourcecites [6] Mahmood I. Misconceptions and Issues Regarding Allometric Scaling during the Drug Development Process Expert Opin. Drug Metab. Toxicol. 2018 14 843 854 10.1080/17425255.2018.1499725 29999428 source
- Partly supportedcites [24] Smoliga J.M. Blanchard O.L. Allometric Scaling Models: History, Use, and Misuse in Translating Resveratrol from Basic Science to Human Clinical Applications FFHD 2017 7 338 10.31989/ffhd.v7i5.345 sourceExperimental — accuracy not yet measured
The Introduction says allometric scaling requires data from at least two species, preferably three. The resveratrol-model section gives a point prediction for a 70 kg human but warns of considerable error because the model uses only two species. The paper does not say that three to four species are typically available or calculate prediction intervals, so it does not support that specific comparison with point estimates. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Kleiber who provided the seminal quantitative synthesis, demonstrating that basal metabolic rate (BMR) scales with body mass to approximately three-quarters of a power law [1,2].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 1. Introduction: Rationale for Allometric Scaling
What the sources say
- Supportedcites [1] Kleiber M. Body Size and Metabolism Hilgardia 1932 6 315 353 10.3733/hilg.v06n11p315 source
Table 1 (p. 8) reports that basal metabolism across thirteen animal groups fits best when expressed relative to body weight raised to the 0.74 power, approximately three-quarters. The General Conclusions (p. 35) propose a weight-power law, while noting that the best-fitting exponent was not conclusively settled. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [2] Kleiber M. Body Size and Metabolic Rate Physiol. Rev. 1947 27 511 541 10.1152/physrev.1947.27.4.511 20267758 source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“pronounced departures from unity therefore flag compounds whose distribution is governed by lipophilic partitioning or tissue binding rather than by bulk physiological volume [6,26].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 3. Mathematics and Diagnostics of the Log–Log Line
What the sources say
- Not checked — no full text of the sourcecites [6] Mahmood I. Misconceptions and Issues Regarding Allometric Scaling during the Drug Development Process Expert Opin. Drug Metab. Toxicol. 2018 14 843 854 10.1080/17425255.2018.1499725 29999428 source
- Partly supportedcites [26] Huh Y. Smith D.E. Rose Feng M. Interspecies Scaling and Prediction of Human Clearance: Comparison of Small- and Macro-Molecule Drugs Xenobiotica 2011 41 972 987 10.3109/00498254.2011.598582 21892879 PMC4181675 sourceExperimental — accuracy not yet measured
The Discussion section, “Relationship between CL and molecular size” (page unavailable), says lipophilicity may influence distribution mechanisms. It does not say that departures of a volume-of-distribution exponent from unity flag lipophilic partitioning or tissue binding; its discussion of allometric exponents concerns clearance. (LLM, conf=0.77)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
90 more claims · 31 with their cited sources checked
Create a free account to see all 205 claims and to verify the 8 references still open.
- It may state two separate claims as one. 98
- Probably not a substantial claim. 18
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 1. Introduction: Rationale for Allometric Scaling
“The mathematical and physiological foundations of these parameters, articulated in the canonical textbook treatment of Rowland and Tozer [12], underpin all of the operational moves that follow.”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > References
“12. Rowland M. Peck C. Tucker G. Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science Annu. Rev. Pharmacol. Toxicol. 2011 51 45 73 10.1146/annurev-pharmtox-010510-100540 20854171”
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174 · cited 4×
“The most conservative estimate should govern FIH initiation, particularly for novel targets and biologics [15,66–68 Step 7: Variability and uncertainty.”
InfluentialA General Model for the Origin of Allometric Scaling Laws in Biology
West, G. B., Brown, J. H., & Enquist, B. J. (1997) · Science · doi:10.1126/science.276.5309.122 · Cited by 5,016 · cited 2×
“West, Brown, and Enquist [3,4] developed a network-based model to explain the mechanistic origin of Kleiber’s three-quarter power law.”
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 2×
“Substituting the human body weight of 70 kg (log 10 [25] = 1.845) gives log 10 (CL) = 0.603 × 1.845 + 0.931 = 2.043.”
InfluentialCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“The mechanism is generally ascribed to disruption of the prostacyclin– thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A 2 production [77,78].”
Kleiber, M. (1932) · Hilgardia · doi:10.3733/hilg.v06n11p315 · Cited by 2,222 · cited 2×
“Still, it was Kleiber who provided the seminal quantitative synthesis, demonstrating that basal metabolic rate (BMR) scales with body mass to approximately three-quarters of a power law [1,2].”
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“The failure stemmed from fundamental immunological differences: the distribution of the CD28 receptor on effector memory T cells in humans versus non-human primates produced a qualitatively different pharmacological response [54,71,72].”
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · cited 2×
“…the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824 · cited 6×
“A subset, however, associates with the triglyceride-rich lipoproteins assembled during lipid absorption and is carried instead into the intestinal lymphatics, entering the systemic circulation at the thoracic duct, and so bypassing the liver on first pass [28,29].”
InfluentialKleiber, M. (1947) · Physiological Reviews · doi:10.1152/physrev.1947.27.4.511 · Cited by 1,817 · cited 1×
“Still, it was Kleiber who provided the seminal quantitative synthesis, demonstrating that basal metabolic rate (BMR) scales with body mass to approximately three-quarters of a power law [1,2].”
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795 · cited 3×
“…filtration and active tubular secretion via OCT2 and MATE transporters, with the result that even modest declines in eGFR translate into exposure increases that allometric body-weight scaling alone would miss, hence the eGFR-based contraindications and dose adjustments in current labelling [46,90].”
InfluentialRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741 · cited 1×
“The mechanism is generally ascribed to disruption of the prostacyclin– thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A 2 production [77,78].”
The Fourth Dimension of Life: Fractal Geometry and Allometric Scaling of Organisms
West, G. B., Brown, J. H., & Enquist, B. J. (1999) · Science · doi:10.1126/science.284.5420.1677 · Cited by 1,718 · cited 2×
“West, Brown, and Enquist [3,4] developed a network-based model to explain the mechanistic origin of Kleiber’s three-quarter power law.”
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 4×
“…and in vitro properties (molecular weight, ionization, and passive permeability for the ECCS; solubility, permeability, and the extent of metabolism for the BDDCS), the class can be assigned before any human data are generated and is therefore available at the first-in-human stage [41,45].”
InfluentialClinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987 · cited 2×
“PBPK verification practice has adopted the same bound, so agreement at this level reflects the practical resolution of the methods rather than genuine mechanistic identity [18,64,100,102,103].”
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978 · cited 6×
“Because the disposition of monoclonal antibodies is dominated by largely conserved catabolic and FcRn-mediated processes rather than by divergent metabolic enzymes, scaling from non-human primates predicts human clearance and volume with an accuracy that small molecules rarely achieve [26,47].”
InfluentialThalidomide-induced Teratogenesis: History and Mechanisms
Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912 · cited 1×
“…the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
Clinical Pharmacokinetics of Tacrolimus
Venkataramanan, R., Swaminathan, A., Prasad, T., Jain, A., Zuckerman, S., Warty, V., McMichael, J., Lever, J., Burckart, G., & Starzl, T. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529060-00003 · Cited by 808 · cited 1×
“Similarly, tacrolimus illustrates how complex binding and metabolism jointly shape both CL and V, creating compound-specific challenges for scaling [17].”
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 1×
“Human dose selection relied on ex vivo human assays and PK/PD modelling anchored in non-human primate data, where cross-reactivity exists [53].”
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776 · cited 1×
“The tissue composition models that underpin volume prediction in PBPK, developed by Rodgers and colleagues, capture ionization and acidic phospholipid binding but tend to underpredict the distribution of basic drugs into lysosome-rich tissues such as the lung [38,39].”
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722 · cited 1×
“…provides a more contemporary illustration of the same principle: rats and dogs do not develop the human-pattern valvulopathy on short-term dosing, and the underlying 5-HT 2 B receptor–driven myofibroblast proliferation on cardiac valves only declared itself with chronic human exposure [57].”
Mammalian basal metabolic rate is proportional to body mass 2/3
White, C. R., & Seymour, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436428100 · Cited by 720 · cited 1×
“…surface-area arguments predict a value closer to 0.67, and a reanalysis of large mammalian datasets found no support for a universal three-quarter exponent, with empirical estimates for individual physiological and pharmacokinetic parameters typically falling between roughly 0.67 and 0.80 [7,8].”
InfluentialTerfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664 · cited 2×
“…metabolism in humans; (ii) the inversion of the parent-to-metabolite exposure ratio under CYP3A4 inhibition, converting a notionally safe prodrug system into a hERG-blockade liability; and (iii) the absence of a routine preclinical assay for QT prolongation before ICH E14 and ICH S7B [82,83].”
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662 · cited 5×
“Use the model to simulate expected human exposures and to test sensitivity to key assumptions and uncertainties [12,22,23,91].”
InfluentialFrom Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654 · cited 3×
“At the same time, medicinal chemistry continues to generate lymphotropic drugs and prodrugs designed to exploit this pathway, whether for first-pass avoidance or for targeting of lymph-resident disease [29,31,32].”
Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Bioavailability
Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00179-x · Cited by 651 · cited 1×
“The integration of allometric scaling with mechanistic absorption, DDI, and elimination modules makes GastroPlus ® applicable to FIH dose selection of orally administered drugs and for label-supportive simulations in special populations [93].”
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 2×
“Extrapolation to a 70 kg reference human with appropriate prediction intervals provides initial estimates of CL, V D , and t½ that bound candidate doses [10,11].”
Mechanism of the Cardiotoxic Actions of Terfenadine
Woosley, R. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500120070028 · Cited by 646 · cited 2×
“…metabolism in humans; (ii) the inversion of the parent-to-metabolite exposure ratio under CYP3A4 inhibition, converting a notionally safe prodrug system into a hERG-blockade liability; and (iii) the absence of a routine preclinical assay for QT prolongation before ICH E14 and ICH S7B [82,83].”
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
Jones, H., & Rowland‐Yeo, K. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.41 · Cited by 626 · cited 3×
“…without genuine predictive validity; transporter abundance values carry substantial measurement uncertainty across donors and tissues; and predictivity for poorly soluble, formulation-sensitive compounds depends heavily on the quality of dissolution and precipitation modelling inputs [12,84,91].”
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616 · cited 2×
“…idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605 · cited 6×
“…and trastuzumab illustrate the more typical situation in which TMDD measurably shapes PK at therapeutically relevant doses, particularly in patients with high tumor burden or shed antigen, requiring two-compartment or full TMDD models rather than empirical allometric extrapolation alone [47,50].”
InfluentialRe-Examination of the “3/4-Law” of Metabolism
DODDS, P. S., ROTHMAN, D. H., & WEITZ, J. S. (2001) · Journal of Theoretical Biology · doi:10.1006/jtbi.2000.2238 · Cited by 589 · cited 1×
“…surface-area arguments predict a value closer to 0.67, and a reanalysis of large mammalian datasets found no support for a universal three-quarter exponent, with empirical estimates for individual physiological and pharmacokinetic parameters typically falling between roughly 0.67 and 0.80 [7,8].”
InfluentialTo Scale or Not to Scale: The Principles of Dose Extrapolation
Sharma, V., & McNeill, J. H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00267.x · Cited by 544 · cited 1×
“These factors differ substantially across preclinical species, and no single allometric exponent can capture their combined effects on oral absorption [15,27].”
The Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
Johnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530 · cited 3×
“Generalization beyond healthy adults requires explicit consideration of physiological diversity that simple allometric scaling cannot capture [22,87–89].”
Lipid-Based Delivery Systems and Intestinal Lymphatic Drug Transport: A Mechanistic Update
Trevaskis, N. L., Charman, W. N., & Porter, C. J. H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.007 · Cited by 442 · cited 5×
“Conventional absorption and bioavailability assessments, and the body-weight regressions built upon them, implicitly assume the portal route and seldom quantify the lymphatic contribution, even though, for suitable compounds, it can represent a substantial fraction of systemic exposure [29,30].”
InfluentialApplied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
Kuepfer, L., Niederalt, C., Wendl, T., Schlender, J., Willmann, S., Lippert, J., Block, M., Eissing, T., & Teutonico, D. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12134 · Cited by 425 · cited 1×
“Its transparency and extensibility have made it increasingly popular in academic and regulatory settings [94].”
Withdrawal of Cerivastatin from the World Market
Furberg, C. D., & Pitt, B. (2001) · Trials · doi:10.1186/cvm-2-5-205 · Cited by 400 · cited 2×
“The rhabdomyolysis risk was concentrated in patients co-prescribed gemfibrozil, an inhibitor of both CYP2C8-mediated cerivastatin metabolism and OATP1B1-mediated hepatic uptake, resulting in several-fold increases in exposure relative to monotherapy [79].”
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397 · cited 2×
“Dedrick’s pioneering analyses of inter-species time-scaling and methotrexate disposition in the early 1970s [13] supplied the conceptual bridge between Kleiber-style biological allometry and quantitative pharmacokinetic extrapolation, anticipating later profile-superposition methods that are now…”
Shebley, M., Sandhu, P., Emami Riedmaier, A., Jamei, M., Narayanan, R., Patel, A., Peters, S. A., Reddy, V. P., Zheng, M., de Zwart, L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1013 · Cited by 395
Man versus Beast: Pharmacokinetic Scaling in Mammals
Mordenti, J. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751104 · Cited by 388 · cited 1×
“The typical allometric workflow begins with PK data generated experimentally in preclinical species (commonly mouse, rat, dog, and non-human primate) [5,6,16].”
Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children
Edginton, A. N., Schmitt, W., & Willmann, S. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645100-00005 · Cited by 357 · cited 2×
“Population PBPK models that embed age-dependent physiology (organ volumes, blood flows, enzyme expression, and renal function) can simulate pediatric exposures and justify bridging strategies based on adult data [22,88,89].”
Pharmacokinetic/Pharmacodynamic Modeling in Drug Development
Sheiner, L. B., & Steimer, J.-L. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.67 · Cited by 351
Theophylline A “State of the Art” Review
Hendeles, L., & Weinberger, M. (1983) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1983.tb04531.x · Cited by 342 · cited 2×
“Theophylline is a classic teaching example: its clearance and volume of distribution scale predictably across species, so body-weight-based projection provides a serviceable first estimate of human exposure [61].”
InfluentialPredicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334 · cited 9×
“…MATE1 and MATE2-K mediate active secretion of hydrophilic cations; metformin is the archetype, its clearance being governed by OCT2-mediated uptake and MATE-mediated efflux rather than by glomerular filtration alone, so its disposition tracks transporter activity rather than body weight [41,46].”
InfluentialClinical Pharmacokinetics of Amiodarone
Latini, R., Tognoni, G., & Kates, R. E. (1984) · Clinical Pharmacokinetics · doi:10.2165/00003088-198409020-00002 · Cited by 333 · cited 1×
“While the allometric exponent for V D commonly approximates 1.0, certain highly lipophilic or tissue-binding drugs, such as amiodarone [33] and digoxin [34], exhibit volumes that are substantially higher than predicted.”
InfluentialRostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331
Pharmacogenetics of Warfarin Elimination and Its Clinical Implications
Takahashi, H., & Echizen, H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00003 · Cited by 312 · cited 1×
“Human-specific cytochrome P450 polymorphisms, such as CYP2C19-mediated omeprazole metabolism [19] and CYP2C9-dependent warfarin elimination [20], can cause human clearance to deviate markedly from allometric predictions.”
Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000180q · Cited by 311 · cited 2×
“…idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300 · cited 1×
“The failure stemmed from fundamental immunological differences: the distribution of the CD28 receptor on effector memory T cells in humans versus non-human primates produced a qualitatively different pharmacological response [54,71,72].”
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300 · cited 5×
“Using multiple species to build the composite normalized curve improves robustness, and the quality of the human prediction depends primarily on the accuracy of the CL and V ss predictions [18,63].”
InfluentialTreiber, A., Schneiter, R., Häusler, S., & Stieger, B. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013615 · Cited by 299 · cited 3×
“Bosentan illustrates this failure mode in concrete terms: hepatic uptake mediated by OATP1B1 and OATP1B3 is the rate-determining step for its disposition, and the same transporter-level mechanism underlies its clinically significant interactions with cyclosporin A, rifampicin, and sildenafil [43].”
Metabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80336-3 · Cited by 286 · cited 3×
“Rosuvastatin provides a complementary example, with OATP1B1-mediated hepatic uptake governing systemic exposure and accounting for the marked increases in exposure observed in carriers of reduced-function SLCO1B1 polymorphisms [44].”
Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285
Approximations of the Target-Mediated Drug Disposition Model and Identifiability of Model Parameters
Gibiansky, L., Gibiansky, E., Kakkar, T., & Ma, P. (2008) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-008-9102-8 · Cited by 272 · cited 1×
“…also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
InfluentialInterspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257 · cited 8×
“The typical allometric workflow begins with PK data generated experimentally in preclinical species (commonly mouse, rat, dog, and non-human primate) [5,6,16].”
InfluentialTGN1412: From Discovery to Disaster
Attarwala, H. (2010) · Journal of Young Pharmacists · doi:10.4103/0975-1483.66810 · Cited by 253 · cited 3×
“The practical consequence for FIH dose selection is that MABEL-based dosing, anchored in human cell or tissue potency assays, generally outranks allometric MRSD estimates for biologics targeting novel pathways [47,54].”
Identification of Human Liver Cytochrome P450 Isoforms Mediating Omeprazole Metabolism
ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A., & BIRKETT, D. J. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb00410.x · Cited by 230 · cited 1×
“Human-specific cytochrome P450 polymorphisms, such as CYP2C19-mediated omeprazole metabolism [19] and CYP2C9-dependent warfarin elimination [20], can cause human clearance to deviate markedly from allometric predictions.”
Estimating the Maximal Potential for Intestinal Lymphatic Transport of Lipophilic Drug Molecules
Charman, W. N. A., & Stella, V. J. (1986) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(86)90027-x · Cited by 217 · cited 3×
“…reaches the systemic circulation while bypassing hepatic first-pass metabolism, it can materially increase the oral bioavailability of affected compounds and lower their apparent first-pass loss in a manner that a body-weight regression of systemic clearance or volume cannot anticipate [28–30].”
Ring, B. J., Chien, J. Y., Adkison, K. K., Jones, H. M., Rowland, M., Jones, R. D., Yates, J. W. T., Ku, M. S., Gibson, C. R., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22552 · Cited by 206 · cited 1×
“PBPK verification practice has adopted the same bound, so agreement at this level reflects the practical resolution of the methods rather than genuine mechanistic identity [18,64,100,102,103].”
Clinical Pharmacokinetics of Phenytoin
Richens, A. (1979) · Clinical Pharmacokinetics · doi:10.2165/00003088-197904030-00001 · Cited by 201 · cited 2×
“…reveal dose-disproportional exposure or saturation, from in vitro evidence that metabolizing enzymes or transporters approach saturation at projected clinical concentrations, and, for biologics, from target expression and binding kinetics that predict target-mediated drug disposition [41,50,65].”
Lave, T. H., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960440h · Cited by 184 · cited 1×
“Compare with allometric predictions and investigate discrepancies [14,42,100,101].”
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase
Kerbrat, A., Ferré, J.-C., Fillatre, P., Ronzière, T., Vannier, S., Carsin-Nicol, B., Lavoué, S., Vérin, M., Gauvrit, J.-Y., Le Tulzo, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604221 · Cited by 171 · cited 1×
“Preclinical species showed adequate tolerability, but off-target effects on lipases beyond FAAH led to CNS toxicity unique to humans at the administered doses [73,74].”
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
Dua, P., Hawkins, E., & van der Graaf, P. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.41 · Cited by 162 · cited 1×
“…from preclinical pharmacokinetic data at this stage and are commonly fixed to in vitro or literature values while the linear disposition parameters are estimated, paralleling the structural and practical identifiability concerns raised for physiologically based models in Section 10.5 [50–52].”
InfluentialFirst‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives
Boxenbaum, H., & DiLea, C. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04011.x · Cited by 161 · cited 2×
“Extrapolation to a 70 kg reference human with appropriate prediction intervals provides initial estimates of CL, V D , and t½ that bound candidate doses [10,11].”
Dong, J. Q., Salinger, D. H., Endres, C. J., Gibbs, J. P., Hsu, C.-P., Stouch, B. J., Hurh, E., & Gibbs, M. A. (2011) · Clinical Pharmacokinetics · doi:10.2165/11537430-000000000-00000 · Cited by 156 · cited 1×
“When only one or two species are available, as is common for biologics, these exponents are typically fixed to consensus values rather than estimated, mirroring the fixed-exponent single-species approach for small molecules described in Section 5.3 [48,49].”
InfluentialThe Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
Huang, S.-M., & Rowland, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.320 · Cited by 150 · cited 3×
“Generalization beyond healthy adults requires explicit consideration of physiological diversity that simple allometric scaling cannot capture [22,87–89].”
Huang, Q., & Riviere, J. E. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.934671 · Cited by 149 · cited 6×
“…and comparing predictions [5]; (iii) biological plausibility constraints informed by known physiological scaling laws and mechanistic models [3,21]; and (iv) model-selection criteria such as the Akaike Information Criterion (AIC) or Bayesian Information Criterion (BIC) to balance fit quality…”
InfluentialCaldwell, G. W., Masucci, J. A., Yan, Z., & Hageman, W. (2004) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190588 · Cited by 148 · cited 2×
“Caldwell et al. [62] examined whether human clearance, volume of distribution, and half-life can be predicted solely from in vivo rat data.”
Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142 · cited 8×
“Because three to four species are typical and uncertainty is substantial, empirical fits should be triangulated against mechanism-aware IVIVE and PBPK model estimates to ensure robustness [14,22,23].”
InfluentialSelf-citationApplications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation
Zou, P., Yu, Y., Zheng, N., Yang, Y., Paholak, H. J., Yu, L. X., & Sun, D. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9332-y · Cited by 138 · cited 3×
“This framework treats allometry as a valuable starting hypothesis, one among several that must withstand scrutiny by mechanism and evidence, while anchoring the ultimate dose selection in the most robust available data [6,22,23,86].”
Marshall, S., Madabushi, R., Manolis, E., Krudys, K., Staab, A., Dykstra, K., & Visser, S. A. G. (2019) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12372 · Cited by 138 · cited 4×
“…DDI prediction: generative models can construct virtual cohorts that span realistic correlations among demographics, genotype, and physiology, while supervised classifiers screen large compound libraries for likely victim or perpetrator behaviour in CYP-or transporter-mediated DDIs [97,98].”
InfluentialLin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03274-2 · Cited by 137 · cited 6×
“Terfenadine is also the canonical example that PBPK platforms now explicitly address through metabolite-linked parent models and DDI simulations [22,84,85].”
InfluentialMachine Learning in Pharmacometrics: Opportunities and Challenges
McComb, M., Bies, R., & Ramanathan, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14801 · Cited by 128 · cited 7×
“…Gaussian process regressions have been deployed to predict in vitro intrinsic clearance, fraction unbound, blood-to-plasma ratio, and other ADME parameters from molecular descriptors, generating priors that feed directly into allometric and PBPK workflows when measured values are unavailable [98].”
InfluentialJones, H. M., Gardner, I. B., Collard, W. T., Stanley, P. J., Oxley, P., Hosea, N. A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539680-000000000-00000 · Cited by 110 · cited 1×
“PBPK verification practice has adopted the same bound, so agreement at this level reflects the practical resolution of the methods rather than genuine mechanistic identity [18,64,100,102,103].”
Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Liric Rajlic, I., & Obach, R. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440282 · Cited by 106 · cited 2×
“PBPK verification practice has adopted the same bound, so agreement at this level reflects the practical resolution of the methods rather than genuine mechanistic identity [18,64,100,102,103].”
Wajima, T., Yano, Y., Fukumura, K., & Oguma, T. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20099 · Cited by 98 · cited 8×
“Using multiple species to build the composite normalized curve improves robustness, and the quality of the human prediction depends primarily on the accuracy of the CL and V ss predictions [18,63].”
InfluentialHuh, Y., Smith, D. E., & Rose Feng, M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.598582 · Cited by 98 · cited 10×
“Recognizing that intrinsic clearance and transporters scale differently with body size and that they affect distinct PK parameters is essential when interpreting interspecies extrapolations [14,26].”
InfluentialNagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96 · cited 3×
“Nagilla and Ward [60] demonstrated that scaling from rat or monkey using LBF-adjusted clearance can yield predictions comparable to those from multi-species allometry for drugs primarily cleared by hepatic metabolism.”
Tang, H., & Mayersohn, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20481 · Cited by 89 · cited 3×
“Nevertheless, the ROE has demonstrated practical utility across numerous examples and remains a useful heuristic in the allometric toolkit [6,58,59].”
Prediction of metabolic drug clearance in humans:In vitro–in vivoextrapolationvsallometric scaling
Shiran, M. R., Proctor, N. J., Howgate, E. M., Rowland-Yeo, K., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600761662 · Cited by 89 · cited 9×
“Because three to four species are typical and uncertainty is substantial, empirical fits should be triangulated against mechanism-aware IVIVE and PBPK model estimates to ensure robustness [14,22,23].”
InfluentialKaur, R., Sidhu, P., & Singh, S. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.189661 · Cited by 89 · cited 1×
“Preclinical species showed adequate tolerability, but off-target effects on lipases beyond FAAH led to CNS toxicity unique to humans at the administered doses [73,74].”
Pharmacokinetics, Bioavailability and Serum Levels of Cardiac Glycosides
Smith, T. W. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80462-9 · Cited by 69 · cited 1×
“While the allometric exponent for V D commonly approximates 1.0, certain highly lipophilic or tissue-binding drugs, such as amiodarone [33] and digoxin [34], exhibit volumes that are substantially higher than predicted.”
InfluentialSpecies Differences in Distribution and Prediction of Human Vss from Preclinical Data
Berry, L. M., Li, C., & Zhao, Z. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040766 · Cited by 69 · cited 1×
“Species-specific differences in plasma protein binding (e.g., α 1 -acid glycoprotein concentrations) or tissue affinity can shift the human estimate far from the allometric prediction [35].”
Sun, Z., Zhao, N., Zhao, X., Wang, Z., Liu, Z., & Cui, Y. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106838 · Cited by 65 · cited 5×
“Sun et al. [85] reported that, between 2019 and 2023, PBPK modelling supported regulatory decisions in the majority of novel drug approvals.”
InfluentialMahmood, I. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991773320 · Cited by 59 · cited 3×
“When the exponent exceeds 1.0, a two-term power equation incorporating CL × BrW and body weight is recommended [6,9].”
InfluentialDisposition and Metabolism of Benoxaprofen in Laboratory Animals and Man
Chatfield, D. H., & Green, J. N. (1978) · Xenobiotica · doi:10.3109/00498257809060392 · Cited by 52 · cited 3×
“In rats and dogs, the elimination half-life was on the order of single-digit hours, whereas in healthy young adult human volunteers, the half-life extended to approximately 20–30 h, a divergence that simple multi-species body-weight scaling could not have anticipated [80].”
Insight into hepatotoxicity: The troglitazone experience†
Watkins, P. B. (2005) · Hepatology · doi:10.1002/hep.20598 · Cited by 45 · cited 2×
“…idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
Trevaskis, N. L., Lee, G., Escott, A., Phang, K. L., Hong, J., Cao, E., Katneni, K., Charman, S. A., Han, S., Charman, W. N., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00458 · Cited by 39 · cited 5×
“Lymphatic mass transport of the lipophilic model drug halofantrine, by contrast, increased in a greater-than-proportional manner with body mass, with an exponent of approximately 1.3, an effect attributed to increased partitioning of the drug into lymph rather than blood as body size increased [31].”
InfluentialAssmus, F., Houston, J. B., & Galetin, A. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.08.014 · Cited by 36 · cited 2×
“…partially resolved the lung discrepancy, and the systematically estimated lysosomal volume fractions, ranging from about 0.03% of cell volume in adipose tissue to several percent in spleen, are currently rat values, leaving the corresponding human and large-animal parameters poorly defined [39,40].”
InfluentialMisconceptions and Issues Regarding Allometric Scaling during the Drug Development Process
Mahmood, I. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1499725 · Cited by 35 · cited 10×
“…in allometric predictions include: (i) prediction intervals and credible intervals for the allometric exponent and projected human parameter [6]; (ii) leave-one-species-out cross-validation, which tests model robustness by systematically excluding each species and comparing predictions [5];…”
InfluentialTang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004135 · Cited by 34 · cited 5×
“Mathematically, these corrections are equivalent to multiplying the predicted human clearance from simple allometry by a constant (F MLP or F BrW ), the value of which depends on the species combination used [58].”
InfluentialSchmitt, M. V., Reichel, A., Liu, X., Fricker, G., & Lienau, P. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000161 · Cited by 19 · cited 2×
“…partially resolved the lung discrepancy, and the systematically estimated lysosomal volume fractions, ranging from about 0.03% of cell volume in adipose tissue to several percent in spleen, are currently rat values, leaving the corresponding human and large-animal parameters poorly defined [39,40].”
InfluentialSmoliga, J. M., & Blanchard, O. L. (2017) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v7i5.345 · Cited by 11 · cited 6×
“Log-linearization makes power-law relationships tractable for least-squares regression, but several data features require discipline and careful interpretation [6,24].”
InfluentialYousef, M., Le, T. S., Zuo, J., Park, C., Chacra, N. B., Davies, N. M., & Löbenberg, R. (2023) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.363591 · Cited by 10 · cited 3×
“…intracellular fraction at the expense of cytosolic unbound drug, lysosomal trapping perturbs the unbound intracellular concentration that drives metabolism and transport, and can therefore bias IVIVE of clearance as well, linking this mechanism to the arguments of Sections 4.3 and 4.4 [37,40].”
InfluentialSelf-citation(1982) · PubMed
Research works printed but not linked: 1
- Institute of Medicine (US) Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials Review of the Fialuridine (FIAU) Clinical Trials Manning F.J. Swartz M. Institute of Medicine (US) Washington, DC, USA 1995 25121268
Cited by
Satapathy, T., Satapathy, A., Sahu, P., & Satapathy, A. (2026) · Biomaterials and Living Medicine for Pharmaceutics · doi:10.1016/j.bioliv.2026.100011
Zhang, L., & Xu, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101256 · Cited by 1
Metadata
- Authors
- Mallillin, M. C., Silva, D. A., Miller, N. A., Zhao, S., Salami, M., Löbenberg, R., & Davies, N. M.
- Affiliations
- University of Alberta (CA)
- Simulations Plus (United States) (US)
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, Canada
- Corresponding author
- Löbenberg, Raimar
- Davies, Neal M.
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2026-07-03
- Volume
- 18
- Issue
- 7
- Pages
- 824
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC13414681
- OpenAlex
- W7167236904
- Cited by
- 2
- References
- 96
- Citations by year
- 2026: 2
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- allometric scaling, first-in-human dose selection, interspecies extrapolation, clearance, volume of distribution, correction factors, in vitro-in vivo extrapolation, physiologically based pharmacokinetic modelling, ADME, target-mediated drug disposition, thalidomide, fenfluramine, rofecoxib, TGN1412, FIAU, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.